Humulin M3 (Insulin Human)

Humulin M3 is indicated for the treatment of diabetes mellitus when a combined rapid‑acting and intermediate‑acting insulin regimen is appropriate.

• Type 1 diabetes mellitus in adults and children requiring basal and mealtime insulin coverage.
• Type 2 diabetes mellitus when oral agents no longer achieve target glycaemic control.
• Adjunct therapy during periods of increased insulin demand, such as illness or pregnancy.
• Transition from separate regular and NPH injections to a single premixed preparation.
• Use in patients who prefer fewer daily injections while maintaining glycaemic stability.

• Humulin M3 delivers both soluble (regular) insulin and protamine‑bound NPH insulin after subcutaneous injection. The regular component rapidly binds to the insulin receptor on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling that promotes translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake in muscle and adipose tissue. The NPH component releases insulin more slowly, sustaining inhibition of hepatic gluconeogenesis and maintaining basal glucose control.

Adverse reactions to Humulin M3 may vary in frequency and severity; they are typically categorized as common or serious.

Common

• Hypoglycaemia, presenting as sweating, tremor, hunger, or confusion.
• Injection‑site reactions such as redness, swelling, or itching.
• Weight gain associated with improved glycaemic control.
• Lipodystrophy at the injection site with repeated use.
• Transient blurred vision during rapid glucose shifts.

Serious

• Severe hypoglycaemia leading to loss of consciousness or seizures.
• Allergic reactions including urticaria, angio‑edema, or anaphylaxis.
• Hypersensitivity to protamine causing systemic symptoms.
• Persistent hyperglycaemia indicating possible insulin resistance or dosing error.

When prescribing or using Humulin M3, clinicians and patients should consider several precautionary measures to minimise risks and optimise therapy.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Educate patients on recognising and treating hypoglycaemia promptly.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Avoid mixing Humulin M3 with other insulin products in the same syringe.
• Monitor blood glucose regularly to detect under‑ or over‑dosing.
• Consider pregnancy status; insulin requirements often change during gestation.

Humulin M3 can interact with other medicines, affecting glucose control or insulin action; awareness of these interactions helps maintain safe therapy.

Avoid

• Concurrent use of sulfonylureas or meglitinides may cause additive hypoglycaemia.
• Beta‑blockers can mask typical hypoglycaemia symptoms, delaying recognition.
• MAO inhibitors have no known direct effect, but close monitoring is advised.

Use with caution

• Corticosteroids may increase insulin resistance, requiring dose adjustments.
• Thiazide diuretics can raise blood glucose levels, potentially reducing insulin effectiveness.
• Alcohol intake can precipitate delayed hypoglycaemia, especially after bedtime dosing.